Chapter 8. Anticoagulant Strategies Targeting Thrombin and Factor Xa
- 1 January 1995
- book chapter
- Published by Elsevier
Abstract
No abstract availableThis publication has 56 references indexed in Scilit:
- Novel antithrombotic approaches to coronary artery diseaseThe American Journal of Cardiology, 1995
- Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasmaBlood Coagulation & Fibrinolysis, 1994
- Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibitionCardiovascular Research, 1994
- A Novel Factor Xa Inhibitor: Structure-Activity Relationships and Selectivity between Factor Xa and ThrombinBiochemical and Biophysical Research Communications, 1993
- Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectorisJournal of the American College of Cardiology, 1993
- Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery diseaseThe American Journal of Cardiology, 1993
- Reversible Tripeptide Thrombin Inhibitors as Adjunctive Agents to Coronary ThrombolysisJournal of Cardiovascular Pharmacology, 1993
- The Structure of a Complex of Recombinant Hirudin and Human α-ThrombinScience, 1990
- Thrombin inhibitors. 1. Ester derivatives of N.alpha.-(arylsulfonyl)-L-arginineJournal of Medicinal Chemistry, 1980